Published by Josh White on 19th March 2019
(Sharecast News) - Oxford BioDynamics announced on Tuesday that it has signed an agreement with Imperial College London, to utilise its latest 'EpiSwitch' biomarker signature for the blood-based diagnosis of prostate cancer in the 'PROSTAGRAM' trial.
URL: http://www.digitallook.com/dl/news/story/28781837/...